Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 | P41231 | 9/20 | 0.45 |
| ▸ | P2RY4 | P51582 | 4/20 | 0.45 |
| ▸ | POLA1 | P09884 | 1/20 | 0.35 |
| ▸ | P2RY6 | Q15077 | 5/20 | 0.33 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.33 |
| ▸ | STING1 | Q86WV6 | 2/20 | 0.33 |
| ▸ | DUT | P33316 | 3/20 | 0.33 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.32 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.32 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.32 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9948510 | 1.00 | P2RY2 (0.45) | P2RY2P2RY4POLA1P2RY6P2RY14 | |
| SCHEMBL20057101 | 1.00 | P2RY2 (0.45) | P2RY2P2RY4POLA1P2RY6P2RY14 | |
| SCHEMBL20057122 | 0.90 | P2RY2 (0.43) | P2RY2P2RY4POLA1P2RY6P2RY14 | |
| SCHEMBL20057119 | 0.90 | P2RY2 (0.43) | P2RY2P2RY4POLA1P2RY6P2RY14 | |
| SCHEMBL9949208 | 0.90 | P2RY2 (0.43) | P2RY2P2RY4POLA1P2RY6P2RY14 | |
| SCHEMBL10150810 | 0.90 | P2RY2 (0.43) | P2RY2P2RY4POLA1P2RY6P2RY14 | |
| SCHEMBL19534566 | 0.84 | P2RY2 (0.46) | P2RY2P2RY4POLA1P2RY6STING1 | |
| SCHEMBL18744163 | 0.84 | P2RY2 (0.46) | P2RY2P2RY4POLA1P2RY6STING1 | |
| SCHEMBL17972352 | 0.81 | P2RY2 (0.44) | P2RY2P2RY4POLA1P2RY6P2RY14 | |
| SCHEMBL21418721 | 0.81 | P2RY2 (0.44) | P2RY2P2RY4POLA1P2RY6P2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3912984-A1 | 4'-FLUORO-NUCLEOSIDES, 4'-FLUORO-NUCLEOTIDES AND ANALOGS THEREOF FOR THE TREATMENT OF HCV | Janssen BioPharma, Inc. (US) | 2021-11-24 | — | — | EP | disclosed |
| EP-2935303-B1 | 4'-FLUORO-NUCLEOSIDES, 4'-FLUORO-NUCLEOTIDES AND ANALOGS THEREOF FOR THE TREATMENT OF HCV | JANSSEN BIOPHARMA INC (US) | 2021-02-17 | — | — | EP | disclosed |
| EP-3421482-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Alios Biopharma, Inc. (US) | 2019-01-02 | — | — | EP | disclosed |
| EP-2655392-B1 | CYCLIC NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA INC (US) | 2018-04-18 | — | — | EP | disclosed |
| US-20170002037-A1 | CYCLIC NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. | 2017-01-05 | — | — | US | disclosed |
| US-20170002037-A1 | CYCLIC NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. | 2017-01-05 | — | — | US | disclosed |
| US-9365605-B2 | Cyclic nucleotide analogs | ALIOS BIOPHARMA, INC. (US) | 2016-06-14 | — | — | US | disclosed |
| US-9365605-B2 | Cyclic nucleotide analogs | ALIOS BIOPHARMA, INC. (US) | 2016-06-14 | — | — | US | disclosed |
| US-20140303108-A1 | CYCLIC NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. | 2014-10-09 | — | — | US | disclosed |
| US-8772474-B2 | Cyclic nucleotide analogs | ALIOS BIOPHARMA, INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-8772474-B2 | Cyclic nucleotide analogs | ALIOS BIOPHARMA, INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-20120165286-A1 | CYCLIC NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| US-20120165286-A1 | CYCLIC NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| WO-2012088155-A1 | CYCLIC NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303108-A1 | CYCLIC NUCLEOTIDE ANALOGS | NT5C2, NTPCR, PNP | P2RY2 100/4885P2RY4 84/4885POLA1 283/4885 |
| US-20170002037-A1 | CYCLIC NUCLEOTIDE ANALOGS | NT5C2, NTPCR, PNP | P2RY2 100/4885P2RY4 84/4885POLA1 283/4885 |
| US-20120165286-A1 | CYCLIC NUCLEOTIDE ANALOGS | NT5C2, NTPCR, PNP | P2RY2 100/4885P2RY4 84/4885POLA1 283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.